Crcm LP Buys 269,851 Shares of Burning Rock Biotech Limited Sponsored ADR $BNR

Crcm LP raised its stake in Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) by 121.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 491,426 shares of the company’s stock after purchasing an additional 269,851 shares during the quarter. Burning Rock Biotech accounts for about 3.3% of Crcm LP’s portfolio, making the stock its 7th largest position. Crcm LP’s holdings in Burning Rock Biotech were worth $9,902,000 at the end of the most recent reporting period.

Separately, Prospera Financial Services Inc acquired a new stake in Burning Rock Biotech in the 3rd quarter valued at about $214,000. 30.03% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Burning Rock Biotech

In related news, Director Yusheng Han bought 314,870 shares of the stock in a transaction on Tuesday, March 31st. The shares were bought at an average cost of $17.36 per share, for a total transaction of $5,466,143.20. Following the purchase, the director owned 17,672,676 shares of the company’s stock, valued at $306,797,655.36. This trade represents a 1.81% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 30.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on BNR. Wall Street Zen lowered Burning Rock Biotech from a “buy” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Monday, April 20th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Burning Rock Biotech Trading Down 2.7%

Shares of BNR stock opened at $8.59 on Friday. The business’s 50 day moving average is $15.44 and its two-hundred day moving average is $21.12. Burning Rock Biotech Limited Sponsored ADR has a twelve month low of $3.06 and a twelve month high of $41.72. The company has a market capitalization of $90.37 million, a P/E ratio of -10.48 and a beta of 1.32. The company has a current ratio of 3.05, a quick ratio of 2.79 and a debt-to-equity ratio of 0.06.

Burning Rock Biotech (NASDAQ:BNR) last announced its earnings results on Tuesday, June 9th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($2.29) by $2.09. Burning Rock Biotech had a negative return on equity of 10.98% and a negative net margin of 11.57%.The company had revenue of $15.66 million for the quarter, compared to the consensus estimate of $19.21 million.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.